MA37941B1 - Dérivés d'aryléthynyle - Google Patents
Dérivés d'aryléthynyleInfo
- Publication number
- MA37941B1 MA37941B1 MA37941A MA37941A MA37941B1 MA 37941 B1 MA37941 B1 MA 37941B1 MA 37941 A MA37941 A MA 37941A MA 37941 A MA37941 A MA 37941A MA 37941 B1 MA37941 B1 MA 37941B1
- Authority
- MA
- Morocco
- Prior art keywords
- formula
- fluorophenyl
- compounds
- derivatives
- enantiome
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La présente invention concerne des dérivés d'éthynyle de formule (i) dans laquelle • r est phényle, 3 -fluorophényle, 4-fluorophényle ou 2,5-di-fluorophényle, • ou un sel d'addition d'acide pharmaceutiquement acceptable, sous forme d'énantiome pur ayant la configuration absolue telle que représentée dans la formule (i). Il a été découvert de manière inattendue que les composés de formule générale i sont des modulateurs allostériques du récepteur de glutamate métabotropique de sous-type 5 (mglur5) qui sont utiles pour le traitement de la schizophrénie, des troubles cognitifs, du syndrome de l'x fragile ou de l'autisme et qui présentent des propriétés biochimiques, physico-chimiques et pharmacocinétiques avantageuses par rapport aux composés de l'art antérieur.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12186265 | 2012-09-27 | ||
| PCT/EP2013/069674 WO2014056710A1 (fr) | 2012-09-27 | 2013-09-23 | Dérivés d'aryléthynyle |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA37941A1 MA37941A1 (fr) | 2016-04-29 |
| MA37941B1 true MA37941B1 (fr) | 2016-11-30 |
Family
ID=47044829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37941A MA37941B1 (fr) | 2012-09-27 | 2015-03-20 | Dérivés d'aryléthynyle |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9221802B2 (fr) |
| EP (1) | EP2900659B1 (fr) |
| JP (1) | JP6027251B2 (fr) |
| KR (1) | KR101737245B1 (fr) |
| CN (1) | CN104684911B (fr) |
| AR (1) | AR092673A1 (fr) |
| AU (1) | AU2013329739B2 (fr) |
| BR (1) | BR112015006218A2 (fr) |
| CA (1) | CA2885382A1 (fr) |
| CL (1) | CL2015000707A1 (fr) |
| CR (1) | CR20150139A (fr) |
| DK (1) | DK2900659T3 (fr) |
| EA (1) | EA025482B1 (fr) |
| ES (1) | ES2594031T3 (fr) |
| HK (1) | HK1207376A1 (fr) |
| HU (1) | HUE029636T2 (fr) |
| IL (1) | IL237596A (fr) |
| MA (1) | MA37941B1 (fr) |
| MX (1) | MX366136B (fr) |
| MY (1) | MY171743A (fr) |
| NZ (1) | NZ706283A (fr) |
| PE (1) | PE20150708A1 (fr) |
| PH (1) | PH12015500538A1 (fr) |
| PL (1) | PL2900659T3 (fr) |
| SG (1) | SG11201502449RA (fr) |
| SI (1) | SI2900659T1 (fr) |
| TW (1) | TWI476194B (fr) |
| UA (1) | UA113779C2 (fr) |
| WO (1) | WO2014056710A1 (fr) |
| ZA (1) | ZA201501678B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA113223C2 (xx) * | 2012-08-13 | 2016-12-26 | Арилетинілпіримідини | |
| NZ703537A (en) * | 2012-10-18 | 2018-06-29 | Hoffmann La Roche | Ethynyl derivatives |
| PT3303316T (pt) | 2015-06-03 | 2020-04-27 | Hoffmann La Roche | Derivados de etinilo |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| WO2006048771A1 (fr) | 2004-11-04 | 2006-05-11 | Addex Pharmaceuticals Sa | Nouveaux derives de tetrazole utilises comme modulateurs allosteriques positifs des recepteurs de glutamate metabotropiques |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| TW200811157A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
| WO2008151184A1 (fr) | 2007-06-03 | 2008-12-11 | Vanderbilt University | Dérivés benzamides modulateurs allostériques positifs récepteurs métabotropiques du glutamate 5 (mglur5) et leurs procédés de fabrication et d'utilisation |
| US8034806B2 (en) * | 2007-11-02 | 2011-10-11 | Vanderbilt University | Bicyclic mGluR5 positive allosteric modulators and methods of making and using same |
| TW201116532A (en) * | 2009-08-05 | 2011-05-16 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
| US8586581B2 (en) * | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
| US8420661B2 (en) | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
-
2013
- 2013-09-23 ES ES13766286.2T patent/ES2594031T3/es active Active
- 2013-09-23 MY MYPI2015000777A patent/MY171743A/en unknown
- 2013-09-23 DK DK13766286.2T patent/DK2900659T3/en active
- 2013-09-23 EP EP13766286.2A patent/EP2900659B1/fr active Active
- 2013-09-23 CN CN201380050037.9A patent/CN104684911B/zh active Active
- 2013-09-23 PE PE2015000422A patent/PE20150708A1/es active IP Right Grant
- 2013-09-23 WO PCT/EP2013/069674 patent/WO2014056710A1/fr active Application Filing
- 2013-09-23 HU HUE13766286A patent/HUE029636T2/en unknown
- 2013-09-23 CA CA2885382A patent/CA2885382A1/fr not_active Abandoned
- 2013-09-23 NZ NZ706283A patent/NZ706283A/en not_active IP Right Cessation
- 2013-09-23 KR KR1020157010351A patent/KR101737245B1/ko active IP Right Grant
- 2013-09-23 AU AU2013329739A patent/AU2013329739B2/en not_active Ceased
- 2013-09-23 JP JP2015533547A patent/JP6027251B2/ja active Active
- 2013-09-23 EA EA201590557A patent/EA025482B1/ru not_active IP Right Cessation
- 2013-09-23 SI SI201330373A patent/SI2900659T1/sl unknown
- 2013-09-23 UA UAA201503791A patent/UA113779C2/uk unknown
- 2013-09-23 SG SG11201502449RA patent/SG11201502449RA/en unknown
- 2013-09-23 PL PL13766286T patent/PL2900659T3/pl unknown
- 2013-09-23 MX MX2015003560A patent/MX366136B/es active IP Right Grant
- 2013-09-23 BR BR112015006218A patent/BR112015006218A2/pt not_active IP Right Cessation
- 2013-09-25 AR ARP130103433A patent/AR092673A1/es unknown
- 2013-09-26 TW TW102134845A patent/TWI476194B/zh not_active IP Right Cessation
-
2015
- 2015-03-05 IL IL237596A patent/IL237596A/en active IP Right Grant
- 2015-03-11 ZA ZA2015/01678A patent/ZA201501678B/en unknown
- 2015-03-12 PH PH12015500538A patent/PH12015500538A1/en unknown
- 2015-03-16 CR CR20150139A patent/CR20150139A/es unknown
- 2015-03-20 MA MA37941A patent/MA37941B1/fr unknown
- 2015-03-20 CL CL2015000707A patent/CL2015000707A1/es unknown
- 2015-03-26 US US14/669,653 patent/US9221802B2/en active Active
- 2015-08-19 HK HK15108049.7A patent/HK1207376A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41134A (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
| TN2014000147A1 (fr) | Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique | |
| MA38080A1 (fr) | Dérivés substitués de phtalazin-1(2h)-one comme inhibiteurs sélectifs de la poly(adp-ribose) polymérase-1 | |
| WO2009005690A3 (fr) | Composés antiviraux | |
| MX2009013733A (es) | Nuevos derivados de acido dicarboxilico como agonistas de los receptores de s1p1. | |
| NZ603108A (en) | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators | |
| MY147588A (en) | (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives | |
| WO2009025839A3 (fr) | Inhibiteurs de phosphodiestérase 10 | |
| MA31834B1 (fr) | 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, leur procédé de production et leur utilisation comme anti-inflammatoires | |
| MA35444B1 (fr) | Ligands du récepteur ep1 | |
| TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. | |
| MX2009013885A (es) | Derivados de quinolina fusionados utiles como moduladores de acido gamma-aminobutirico. | |
| MX337443B (es) | Derivados de etinilo como moduladores alostericos positivos del receptor de glutamato metabotropico del subtipo 5 (mglur5). | |
| MA37941B1 (fr) | Dérivés d'aryléthynyle | |
| UA103329C2 (ru) | Соли соединений-ингибиторов вич | |
| MA34173B1 (fr) | Hhétérobiaryl-cyclohexyl-tétraazabenzo[e]azulènes | |
| EA014959B3 (ru) | Ингибиторы глицинового переносчика-1 | |
| MA31863B1 (fr) | Dérivés de pyrazole comme inhibiteurs de 5-lo | |
| MA38659B1 (fr) | Dérivés éthynyle comme antagonistes du récepteur métabotrope du glutamate | |
| TN2012000285A1 (fr) | NOUVEAUX DERIVES D' (HETEROCYCLE-PIPERIDINE CONDENSEE)-(PIPERAZINYL)-1-ALCANONE OU D' (HETEROCYCLE-PYRROLIDINE CONDENSEE)-(PIPERAZINYL)-1-ALCANONE ET LEUR UTILISATION COMME INHIBITEURS DE p75 | |
| IN2013DN02555A (fr) | ||
| MX2012001799A (es) | Derivados de pirrolidina como antagonistas del receptor de neuroquinona 3 (nk3). | |
| PH12015500261A1 (en) | Arylethynyl pyrimidines | |
| PH12015500496B1 (en) | Ethynyl derivatives as modulators of mglur5 receptor activity | |
| MA37879B1 (fr) | Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant |